



PFOA-Induced Health Effects

Suzanne (Sue) Fenton, PhD

Reproductive Endocrinology Group Leader

NTP Laboratory, Division of the National Toxicology Program

National Institute of Environmental Health Sciences

December 2, 2019

NC SSAB



Raleigh, NC



Per- and Poly-Fluoroalkyl Substances (PFAS)

- Non-stick, water/grease/friction repellent, stain resistance
 - Over 5,000 compounds; structurally diverse
 - PFOA (C8) was used as a polymer processing aid in preparation of Teflon and in textile coating processes; an emission and degradation product
 - PFOS (C8) - Scotchgard and Gore-Tex
- PFOS historical presence in MIL SPEC Aqueous film forming foam (AFFF); wide distribution across the U.S. military installations, airports, fire fighting training sites
- Hundreds of other applications, e.g. cosmetics, dental floss, wiring, waxes, polishes, paints, food contact surfaces, etc.
- PFAS known for age, sex, species, and strain-specific ADME
- PFOA and PFOS - “*Suggestive Evidence of Carcinogenic Potential*” based on US EPA (2005 & 2016) and International Agency for Research on Cancer (IARC V110 PFOA; 2016)

PFOA



PFOS



Use of the Developing Mouse Model



Dawes et al. 2001

Absorption, distribution, metabolism, and excretion are all modified in fetus & pregnant female compared to adult male

- Clearance rates of PFAS vary between chain lengths, species, and genders:
 - ✓ Half-lives of long chain lengths >> those of short chain lengths (w/exception)
 - ✓ Half-lives of humans >> monkeys >> rodents
 - ✓ Half-lives of long-chained PFAS in male rats >> those of females (gender differences are smaller in other species)
- Internal dose measurements necessary



	PFBS (C4)		PFHxS (C6)		PFOS (C8)		PFBA (C4)		PFHxA (C6)		PFHpA (C7)		PFOA (C8)	
	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male
<i>Rat</i>	4.0 hours	4.5 hours	1.8 days	6.8 days	62-71 days	38-41 days	1.0-1.8 hours	6-9 hours	0.4-0.6 hours	1.0-1.6 hours	2.4 hours	1.2 hours	2-4 hours	4-6 days
<i>Mouse</i>	2.1 hours	3.3 hours	25-27 days	28-30 days	31-38 days	36-43 days	3 hours	12 hours	~1.2 hours	~1.6 hours			16 days	22 days
<i>Monkey</i>	3.5 days	4.0 days	87 days	141 days	110 days	132 days	1.7 days		2.4 hours	5.3 hours			30 days	21 days
<i>Humans</i>	28 days		8.5 years		4.3-5.0 years		3 days		32 days		1.2 years		2.1-3.8 years	

Table courtesy of Dr. Chris Lau, U.S. EPA



PFOA Exposure Increases with Breastfeeding

- Infants have higher exposures from breast milk or formula:
 - PFOA levels in breast milk similar or higher than in maternal drinking water
 - Ingest much more fluid per body weight than older individuals
- PFOA transfers in mouse milk (Fenton et al. 2009; Reiner et al. 2009)
- Sensitive subpopulation for developmental and other short-term effects






PFOA Alters Mammary Function & Offspring Outcomes


Significant increase
in mouse pup
mortality at 5 mg
PFOA/kg BW

taken from Lau et al., 2006 *Toxicol Sci*



Impaired lactation in
mice exposed to
5 mg PFOA/kg BW

White et al., 2007 *EHP*



Significant decrease in mouse pup birth weight at 5 mg PFOA/kg BW
(reviewed in Navigation Guide Systematic Review – Koustas et al. 2014 *EHP*)



Prenatal & Postnatal Exposure Effects in Mice




A

PND 22




PND 42

PND 63




Control





Lactational Exposure (5L)



Intrauterine Exposure (5U)











Intrauterine + Lactational Exposure (5U+L)



B

18 months



5U + 5L = mice exposed to 5 mg PFOA/kg/d
5L = PFOA transfer via milk after in utero exposure ended


from White et al. 2009, *Reprod Toxicol*



Persistence of Mammary Gland Effects

CD-1 mice, GD 1-17 exposure, @ 18 mon

Control



5 mg/kg

White et al. 2009, *Reprod Toxicol*


Adult CD-1 mice, GD 1-17 exposure

Control

0.3 mg/kg

1.0 mg/kg

PND 84



Macon et al. 2011, *Toxicol Sci*



Mouse Serum PFOA Concentrations (ng/ml)

Days after PFOA ended	Control	0.01 mg/kg	0.1 mg/kg	1.0 mg/kg
7	6.7 ± 1.1 (5)	149.5 ± 11.7 (4)*	1113.5 ± 57.2 (4)*	9163.5 ± 629.7 (3)*
14	4.9 ± 1.2 (4)	95.0 ± 13.3 (3)*	747.7 ± 38.2 (4)*	6448.8 ± 328.3 (5)*
21	< 5, LOQ (5)	29.3 ± 12.5 (4)*	201.0 ± 27.1 (5)*	2250.0 ± 170.8 (5)*
28	< 5, LOQ (5)	8.0 ± 1.0 (5)*	64.0 ± 12.8 (5)*	1249.4 ± 227.6 (5)*
56	< 5, LOQ (5)	< 10, LOQ (5)*	13.1 ± 1.9 (5)*	57.9 ± 18.6 (5)*

Data are presented as mean ± SEM. Significant effects compared to controls by Dunnetts, *p<0.05

Ohio River Valley children's serum PFOA concentrations:

- ≤600 ng/ml (Ages 2-5; Emmett et al. 2006)
- 77.6 ng/ml (Ages <12; Frisbee et al. 2009)
- 59.9 ng/ml (Ages 12-19)



<http://www.c8sciencepanel.org/>

* Significant mammary effects present at these doses (Macon et al. 2011, *Tox Sci*)

Similar mammary effects reported in C57Bl/6J mice exposed in utero, but at higher PFOA exposures (0.3 mg/kg LOAEL) – Tucker et al. 2015, *Reprod Toxicol*



Abnormal Mouse Mammary Gland Development


- **Sensitive target** – Occurs in mouse offspring at doses/serum levels below those that increase offspring liver weight
 - *To date, sensitive mouse developmental effects such as delayed mammary gland development and others have been taken into consideration in 7 states, resulting in use or proposed use of database uncertainty factors of 3 or 10: Corder et al 2019 JESEE PMID: 30622333*
- **Well established** – 9 mouse studies; from gestational and/or lactational exposure
 - *Only one negative study; used different exposure scenario/strain*
 - *Differing mouse strain susceptibility consistent with toxicokinetic differences*
- **Adverse** – Structural changes persist until adulthood; effect on lactation
- **Human relevance** – Mice and humans have similar mode of action
- Accumulating data on effects on lactational function/duration in women
 - *Breast development evaluated in only one study of adolescents*
 - *Several human studies associate PFOA with ↓ duration of breastfeeding*




PFAS Affect Breastfeeding Duration in Women

From Romano et al. 2016, *Environ Res*

Product-Limit Survival Estimates



Breastfeeding duration difference at doubled exposure



From Timmermann et al. 2017, *Reprod Toxicol*



Prenatal PFOA & Early Adult Obesity in Mice





Highlighted in Holtcamp 2012 *Environ Health Perspect* PMID: 22296745

Data in Hines et al, 2009 *Mol. Cell Endocrinol.* 304: 97-105

Supported in epidemiological studies:

1. Increased gestational weight gain
[Int J Environ Res Public Health](#) 2016
2. Overweight in 20 yr old Danish daughters exposed in utero.
[Environ Health Perspect](#) 2012

Mechanisms are not understood – Likely more than one





PFOA Induces Liver Tumors in CD-1 & PPAR- α KO Mice


In Filgo et al. 2015, *Toxicol Pathol*

- Three strains of mice compared for effects of prenatal PFOA exposure on liver at 18 months of age
- Centrilobular hepatocyte hypertrophy significantly increased in incidence with PFOA dose in CD-1 and 129/Sv PPAR α -KO mice, and increased in severity in the 129/Sv WT mice.
- Hepatocellular adenomas (HA) were significantly increased in CD-1 mice (0.3 mg/kg), but no significant dose-response. HA were also evident in over 13% of PFOA-exposed PPAR α -KO mice; these lesions are stimulated by prenatal PFOA exposure, a process which may be independent of PPAR α activation.
- A dose dependent trend in hemangiosarcomas was evident in CD-1 mice
- Hepatocellular adenomas were not found in historical CD-1 control female mice (485 mice examined; Giknis and Clifford, 2010).
- Bile duct hyperplasia and hematopoietic cell proliferation were two liver lesions that were only significantly increased with increasing dose of PFOA in the PPAR α -KO mice




Hepatocellular Hypertrophy in CD-1 Mice

Control liver TEM



1 mg PFOA/kg/d
liver TEM


Hepatocellular Hypertrophy





A Lingering National Problem

PFOA isn't being produced or used in U.S. manufacturing anymore



Hu et al. 2016, ES&T Letters 81% associated with manufacturing site

- Many areas have not been sampled – well and small community water sources
- Other sensitive end points – immune system and placenta

Thanks for your attention!

Questions?

suzanne.fenton@nih.gov

